Concert Pharma (CNCE) Reports Q2 EPS of $0.16

Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of $0.16, versus ($0.41) reported last year. Revenue for the quarter came in at $32 million, versus $6.4 million reported last year.

For earnings history and earnings-related data on Concert Pharma (CNCE) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• INVO Fertility (IVF) Tops Q2 EPS by 105c
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance